Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
55354-1-PBS targets JMJD3 in WB, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | Peptide 相同性解析による交差性が予測される生物種 |
| Full Name | jumonji domain containing 3, histone lysine demethylase |
| Calculated molecular weight | 177 kDa |
| Observed molecular weight | 177 kDa |
| GenBank accession number | NM_001080424 |
| Gene Symbol | JMJD3 |
| Gene ID (NCBI) | 23135 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | O15054 |
| Storage Buffer | PBS Only |
| Storage Conditions | Store at -80°C. |
Background Information
JMJD3, also known as KDM6B, is a 1643 amino acid protein, which belongs to the UTX family. JMJD3 is a Histone demethylase that specifically demethylates 'Lys-27' of histone H3, thereby playing a central role in histone code (PubMed:17825402, PubMed:17851529, ). JMJD3 demethylates trimethylated and dimethylated H3 'Lys-27', so it Plays a central role in regulation of posterior development, by regulating HOX gene expression (PubMed:17851529). Histone demethylases are epigenetic actors with a crucial role in cancer by acting as suppressors of tumors or as oncogenes. JMJD3 and UTX (ubiquitously transcribed tetratricopeptide repeat, X chromosome) are transcription activators, being specific H3K27me3 demethylases. JMJD3 is involved in many cellular process such as development, differentiation, senescence and aging by p16, p53 and RB pathways and finally inflammation. Depending on cancer type, JMJD3 expression is increased (prostate and breast cancers, melanoma, gliomas, renal cell carcinoma or decreased (lung, liver, pancreatic, colon and colorectal cancers. This role in carcinogenesis has allowed the development of "epidrugs" to modulate JMJD3 expression (PMID: 29805743 ).